# Difference In-Gel Electrophoresis: A High-Resolution Protein Biomarker Research Tool

g

# David S. Gibson, David Bramwell, and Caitriona Scaife

#### Summary

16 Difference in-gel electrophoresis (DIGE) is a recent adaptation of conventional two-17 dimensional gel electrophoresis (2-DE) that incorporates novel fluorescent labels, has 18 multiplex attributes, and boasts software-assisted image analysis. Combined, these character-19 istics offer significant benefits in accuracy and reproducibility to quantify differential protein expression levels between biological samples. The DIGE technique and materials required 20 to perform it are described in detail within. The principles behind consistent gel image 21 acquisition and reliable image analysis are also considered. Within the context of biomarker 22 and drug target discovery, this method simplifies analysis, increases sample throughput, and 23 represents a reliable 2-DE platform.

24 25

01

02

04 05

06 07

08 09 10

**Key Words:** Biomarker; Cy dye; DIGE; fluorescent difference in-gel electrophoresis; proteomics; two-dimensional gel electrophoresis

26 27 28

29

30

# 1. INTRODUCTION TO DIFFERENCE IN-GEL ELECTROPHORESIS

Two-dimensional gel electrophoresis (2-DE) is an established platform that facilitates the analysis of complex protein mixtures. O'Farrell was first to introduce high-resolution two-dimensional electrophoresis by resolving proteins to individual isoelectric point and molecular weight coordinates (1). The main asset of this method is that it provides a global view of the state of proteins within a sample. In theory, thousands of proteins can be visualized at once, giving a unique qualitative "map" or "fingerprint" of changes

39

From: Methods in Pharmacology and Toxicology: Biomarker Methods in Drug Discovery and Development Edited by: F. Wang © Humana Press, Totowa, NJ

between given samples. Though many developments, such as standardized 01 immobilized pH gradients, have led to vast improvement in inter-run 02 consistency, deficiencies in sensitivity and spot matching have necessi-03 tated further adaptation using fluorescent stains. Comparison between large 04 groups of conventionally (silver or Coomassie) stained gels is complicated 05 by spot to spot warping, caused by variations in sodium dodecyl sulfate-06 polyacrylamide gel electrophoresis (SDS-PAGE) gel casting, electric and 07 pH fields, and thermal fluctuations during electrophoresis. This leads to 08 problems in spot matching and necessitates multiple gel replicates to prevent 09 assumptions on mismatched proteins. In other words, gel to gel hetero-10 geneity makes it difficult to distinguish with confidence between variations 11 in the technique and those of genuine induced biological change, such as 12 in disease states (2). Difference in-gel electrophoresis (DIGE) addresses a 13 number of these issues in that two to three samples can be subjected to 14 exactly the same running conditions within a single gel. Unlu et al. developed 15 DIGE to allow a more direct and reproducible comparison between protein 16 samples, differentiated by prelabeling with spectrally resolvable fluorescent 17 cyanine, or Cy, dyes (3). The Cy dyes are charge matched with the residues 18 they bind to within the proteins of a given sample and have similar 19 molecular weights (0.5 kDa), thus result in only slight gel shifts. The Cy 20 dyes are based on extended organic ring structures and hence are highly 21 hydrophobic. Concerns with protein precipitation prior to electrophoresis 22 have been surmounted by using a "minimal labeling" strategy, whereby 23 binding is limited to only 1% to 2% of lysine residues available within a 24 sample (4). 25

Excitation of each fluor allows the creation of a digital image of each 26 individually labeled sample. These dyes give additional validity to the two-27 dimensional technique in the form of higher sensitivity, wider dynamic 28 range, and linearity of detection. Detection limits of 0.025 ng are possible, 29 with a dynamic range around five orders of magnitude. One of the strongest 30 features of the technique, however, is the ability to include an internal pooled 31 standard, which is loaded on all gels within an experiment (5). The internal 32 standard permits the linking of all gels in an experiment, thus offering 33 more reliable and intuitive software-assisted comparisons. The accuracy of 34 protein quantification between samples is increased dramatically, and much 35 smaller changes in protein expression can be studied with greater confi-36 dence. Evaluations of DIGE alongside traditional and more recent proteomic 37 methods using isotope-coded or isobaric tags (cICAT and iTRAQ) reveal 38 that it remains competitive in sensitivity and can be used with confidence 39 as a platform for drug discovery and development (4,6). 40

41

### 01 2. DIGE EXPERIMENT CONSIDERATIONS

02 Because three cyanine dyes are available, up to three separate protein 03 samples can be labeled per gel. A pairwise analysis and organization could 04 also be used (akin to gene chip analysis), where control versus drug-treated 05 samples are labelled with Cy3 and Cy5 only. When normalization of expression 06 levels is desired across a number of different experiments and within the 07 one experiment, adequate quantities of each sample should be available to 08 create a common pooled internal standard. The internal standard can be distin-09 guished from experimental samples by labeling with Cy2 dye. Anomalies in 10 spot intensity due to preferential labeling can be eliminated by randomized or 11 reciprocal labeling, in which half of each experimental group is labeled with 12 Cy3 and the other with Cy5 (7). In order to distinguish intrinsic, interindi-13 vidual biological variation from genuine changes in protein expression, 14 biological replicates should be included in each experimental group. A recent 15 study focused on the DIGE technique has shown that a minimum of four 16 replicate gels is required to maintain a 95% chance of avoiding false 17 negatives, when a twofold change in expression is considered significant (8). 18

# 19 20

#### **3. SAMPLE PREPARATION**

Plasma and synovial fluid are used in this chapter to illustrate and describe 21 the steps required for the purification and minimal fluorescent labeling of 22 body fluid samples. For details of how to prepare cell lysates, with both 23 minimal and saturation types of labeling, one can refer to the Ettan DIGE 24 system user manual (9). The following reagents and conditions have been 25 used in our laboratory to produce reliable data with clinical relevance to 26 patient outcome but could also be applied to prospective drug trial to monitor 27 therapeutic response. Sample preparation should be consistent and kept as 28 simple as possible to reduce inter-run inconsistencies. Protein modifications 29 during sample preparation must be prevented, particularly degradation due 30 to endogenous proteolytic enzymes. Such changes in samples analyzed by 31 gel-based approaches can translate into misleading artifact spots with novel 32 molecular weights.

33 34

35

# 3.1. Sample Purification and Assay

Cellular or particulate material should be removed from the body fluid by centrifugation prior to any further purification steps. This circumvents contamination by sub-proteomes other than that of the body fluid that is to be analyzed. Endogenous protease activity should be inactivated for reasons already eluded to above. A number of approaches are possible, with

AQ1

AQ2

AQ3

varying consequences to the resulting sample integrity. Protease inhibitor 01 cocktails (such as the Complete Protease Inhibitor Cocktail Tablets; Roche) 02 can be used to inactivate a wide variety of degradative enzyme classes 03 including cysteine, matrix metallo and serine proteases. This remains our 04 preferred method of body fluid stabilization, and an adaptation is now 05 also available, in the form of a blood tube with proprietary inhibitors for 06 immediate and convenient sample protection (BD P100). Some authors, 07 however, caution against their use in certain applications, as artifacts can 08 result from modified protein charge, or peptide-based inhibitors such as 09 leupeptin may interfere with mass spectrometry analysis (10,11). Proteases 10 may also be inactivated by high or low pH extremes with Tris buffer or 11 trichloroacetic acid (TCA), respectively, or alternatively total protein can 12 be precipitated by TCA/acetone. In balance though, protein yield may be 13 diminished by incomplete precipitation or resolubilization. Once stabilized, 14 salts can be removed from protein samples (if higher than 10 mM) by 15 dialysis with low-molecular-weight cut-off membranes, though if analysis 16 of small peptides is desired, precipitation could be implemented. Other 17 macromolecules such as lipids, polysaccharides, and nucleic acids should be 18 removed by organic solvent, unless present at low concentrations (as with 19 plasma). The sample can be lyophilized if concentration is necessary (5 to 20 10 mg/mL is an ideal protein concentration, though labeling of 1 mg/mL is 21 possible) and resuspended in a minimal quantity of DIGE-compatible lysis 22 buffer [DLB; 30 mM Tris, 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, pH 23 8.5]. Ampholytes and dithiothreitol (DTT) are omitted from the lysis buffer 24 prior to the labeling reaction as both primary amines and thiol groups will 25 compete with the proteins for the available Cy dye. The pH of the sample 26 to be labeled is also critical to the reaction, so check that the sample pH is 27 8.5 by spotting on a pH indicator strip and, if necessary, make drop-wise 28 adjustments with dilute sodium hydroxide. The concentration of protein in 29 each sample should be assayed either by Bradford reagent or using the 30 proprietary Ettan 2D Quant kit (GE Healthcare). 31

# 3.2. Sample Labeling

32

Aside from the pH and protein concentration recommendations already 34 made, the efficiency of minimal dye labeling is dependent on the ratio of 35 dye to protein (400 pmol Cy dye to 50 µg protein is cited in the DIGE 36 user manual; GE Healthcare). The Cy dye fluors should be reconstituted 37 in anhydrous dimethyl formamide under the manufacturer's guidelines to 38 create a 1 mM stock solution. Each has a characteristic deep color as follows: 39 Cy3, red; Cy5, blue; and Cy2, yellow (as shown in Fig. 1). The sample and 40 dye quantities required for a six-gel, three-dye pilot experiment are shown 41

24

25

26



193

#### Difference In-Gel Electrophoresis

**Fig. 1.** Schematic representation of the laboratory procedures involved in a typical DIGE experiment.

in the following worked example (Table 1). Paired plasma and synovial 27 fluid samples from six patients (A–F) are labeled with Cy3 and Cy5. An 28 experimental design incorporating randomization of sample labeling and 29 loading across gels is demonstrated to avoid systematic errors. An internal 30 pooled standard is generated by combining equal amounts of all matched 31 plasma and synovial fluid samples, followed by Cy2 dye labeling. Sufficient 32 pooled internal standard is prepared to allow enough aliquots for each gel 33 in the experiment. It is also prudent to create a slight excess (10% to 20%)34 of each dye reaction to ensure a complete aliquot is loaded on each gel. 35 Thus for the individual plasma and samples, 60 µg is labeled with Cy3 36 or Cy5, but only 50 µg will be loaded of each. A single internal standard 37 is therefore prepared, which comprises 30 µg of each of the 12 samples 38 (6 plasma and 6 synovial fluid) and labeled with Cy2 dye. Before labeling, it 39 is recommended that all sample concentrations are normalized to 10 µg/µL, 40 41 to make subsequent pipetting easier (Table 2).

01 Table 1

19 20

21

32

33

34

35

194

The Sample and Dye Quantities Required for a Six-Gel, Three-Dye Pilot
 Experiment Are Shown for a Three-Dye Run Analyzing Plasma (PL) and
 Synovial Fluid (SF) from Six Patients (Anonymized as A, B, C, D, E, and F)

Gel	Cy2 pooled standard	Cy5	СуЗ
1	50 μg (4.17 μg of each sample SF A–F and PL A–F)	50 µg of <b>PL</b> C	50 µg of <b>SF</b> D
2	50 μg (4.17 μg of each sample SF A–F and PL A–F)	50 µg of <b>SF</b> A	50 μg of <b>PL</b> F
3	50 μg (4.17 μg of each sample SF A–F and PL A–F)	50 μg of <b>PL</b> B	50 μg of <b>SF</b> E
4	50 μg (4.17 μg of each sample SF A–F and PL A–F)	50 µg of <b>SF</b> C	50 μg of <b>PL</b> A
5	50 μg (4.17 μg of each sample SF A–F and PL A–F)	50 μg of <b>PL</b> D	50 µg of <b>SF</b> B
6	50 μg (4.17 μg of each sample SF A–F and PL A–F)	50 µg of <b>SF</b> F	50 μg of <b>PL</b> E

### Beforehand: Label Reaction Tubes

- Label 12 Microfuge tubes (0.5 mL) as Table 2 (SF A-F, PL A-F) for preparation of samples prior to labeling.
- 2. Label a second fresh set of 12 Microfuge tubes as above, for the labeling reaction.
   25. Label a second fresh set of 12 Microfuge tubes as above, for the labeling reaction.
- $\frac{25}{26}$  3. Label one Microfuge tube as *PS* for the pooled standard.
- <sub>27</sub> Sample Preparation
- 4. Aliquot volumes of each sample equivalent to 100 μg into each of the first
  set of SF or PL individually labeled tubes. Adjust protein concentrations of all
  samples to 10 μg/μL by addition of DIGE compatible lysis buffer (DLB), as
  shown in Table 1/2
- AQ4
- 5. Aliquot 6  $\mu$ L of each normalized sample (60  $\mu$ g) from the above, into each of the second fresh set of *SF* or *PL* individually labeled tubes and 3  $\mu$ L (30  $\mu$ g) of each sample into the one *PS* labeled tube. This gives a total of 36  $\mu$ L (or 360  $\mu$ g protein) in the pooled standard tube (*PS*).

#### 36 Sample Labeling

6. The Cy dyes are diluted from 1 mM stock concentration to a working concentration of 400 pmol/μL with DMF, and 1.2 μL of the Cy3 and Cy5 dyes is added to individual samples in a randomized fashion as described in Table 1. An aliquot of 7.2 μL of 400 pmol/μL Cy2 is added to the pooled standard tube. (*Note*: Only reconstitute minimal quantities of Cy dye working dilutions for

			1													ı
01		tube				~		_	,		<b>.</b> .	~				
02		ing	) <	E B C	L C	FD	FΕ	FΕ	LA	ΓB	L C	ΓD	LE	LΕ		
04		lbel	U U		S	S	S	S	Р	Ч	Ч	Р	ď	ď		
05	n*	La														
06	MO	50														
07	Sh	ling														
08	re	d tc abe														
09	s A	ad ad L)	v v	9	9	9	9	9	9	9	9	9	9	9	PS	
10	ion	ime ridu s (u	-													
11	acti	olu Idiv Ibes														
12	Rea	5 E. C														
13	ye	$\sim$									4					
14	<u>Ó</u>	o P UL	-													
15	led	ld to be (														
16	00	tul	, 7	n (n	3	З	З	З	ς	Э	$\mathfrak{c}$	m	$\mathfrak{c}$	$\mathfrak{C}$	36	
17	d F	ume ling	,						1							
18	an	/olı abe]						4								
19	ıal															
20	idι	- G														
21	div	DLE (ul	;							7						
22	In	ht D	.   .	1 0	3	S	ю	4	S	0		2	8	8		
23	for	ne c ug	) v	. v		-	4	6.	۲.	٦.	5.	6.	S.	6.		
24	pa	lun 10				1										
25	uire	Vo for														; <b>&lt;</b>
26	edı															Iµ/g
27	t R	.) ed														й 0
28	en	luir (uL	,													0 1
29	ilu	ne U		9. t . t	5.7	8.5	5.7	3.6	2.5	2.8	4.3	3.8	4.2	3.2		ed 1
30	D	00											•			aliz
31	anc	olu or 1													daro	orm
32	es	⊳ fi	$\mathcal{I}$												tano	e n
33	lqı	T													al s	IS al
34	an	1/ar													erné	tion
35	of S	l a		9.2	7.6	1.8	7.4	7.6	9.4	5.5	3.2	6.5	3.6	1.4	inte	ntra
36	SS C	otei	1	10	-	1	1	0	$\mathfrak{c}$	З	0	0	0	$\mathfrak{c}$	led	nce
37	me	[Pro													000	c co
38	2 olu														or p	nple
39	ole c V	Inle		, a	υ	D	Ш	Ľ	A	В	U	D	Щ	Ĺ	al f(	San
40	rat The	Jam		Ē	H	H	H	H	L	J	J	T	L	J	Γotέ	*
41			I U			<b>(</b>			Ì	H	Ĩ	Ĭ	Ĩ	I	<u> </u>	

195

Difference In-Gel Electrophoresis

Book\_Wang\_9781597454636\_Proof1\_December 31, 2007

<ul> <li>the experiment as any remaining stock can be kept for future work at -20°C for 3 months.)</li> <li>7. All labeling reaction tubes should be mixed thoroughly by pipette and vortex and pulse-centrifuged to collect the mixture at the bottom. Incubate the labeling reaction tubes on ice in the dark for 30 min. (<i>Note</i>: Subsequent exposure of all dye reactions to ambient light, whether in IPG strip or gel, should be minimized to prevent degradation/bleaching of the fluorophore.)</li> <li>8. Add 1.2 µL of 10 mM lysine to each of the Cy3 and Cy5 dye reactions and 7.2 µL to the Cy2 dye reaction to stop the labeling. Again, mix and centrifuge briefly before incubating for a further 10 min on ice in the dark. The labeling reaction is now complete, and labeled samples can be stored for up to 3 months at -70°C in a light protected container, if not used immediately.</li> </ul>
4. FIRST-DIMENSION ISOELECTRIC FOCUSING (IEF)
The ampholytes and DTT that had been omitted prior to the labeling are added at this point in the form of a 2X sample buffer. The sample is denatured with dithiothreitol (DTT) and a volume equivalent to 50 $\mu$ g of each individual Cy3 and Cy5 labeled sample are then combined with 50 $\mu$ g of the Cy2 pooled internal standard. The mixture is subsequently rehydrated onto 24-cm immobilized pH gradient (IPG) strips for highest resolution (sample in-gel rehydration). Samples with larger quantities of high molecular weight proteins, alkaline proteins, or hydrophobic proteins are likely to be poorly absorbed into the IPG strip gel matrix and would benefit substantially from cup loading detailed elsewhere ( <i>12</i> ).
Beforehand: Prepare Buffers
<ol> <li>Prepare 2X sample buffer [8 M urea, 130 mM DTT, 4% (w/v) CHAPS, 2% (v/v) IEF ampholytes 4–7] and rehydration buffer (8 M urea, 13 mM DTT, 4% (w/v) CHAPS, 1% (v/v) IEF ampholytes 4–7].</li> <li>Remove pH 4–7 IPG strips from freezer to thaw on bench and ensure rehydration tray is level. Note strip numbers and label six fresh microcentrifuge tubes as Table 1 (1–6).</li> </ol>
Pooling Samples, Strip Rehydration, and Isoelectric Focusing
<ol> <li>Add equal volumes of 2X sample buffer to individual Cy3 and Cy5 labeled samples (8.4 μL each) and to the Cy2 labeled pooled standard (50.4 μL), mix and leave on ice for 10 min (each tube now has 50 μg labeled protein in 14 μL).</li> <li>Aliquot 14 μL of each Cy3, Cy5, and Cy2 labeled samples to be focused on the same IPG strip into the tubes as indicated in <b>Table 1</b>. Add 408 μL of rehydration buffer to each tube, mix, and centrifuge briefly.</li> <li>Pipette each mixture into a separate channel of the rehydration tray. Peel off the protective cover from the IPG strip and carefully lower it gel side down into the rehydration buffer-sample; remove any air bubbles with a pipette tip.</li> </ol>

#### Table 3 01

11

Isoelectric Focusing Conditions Appropriate to Proteins Soluble Within 02 the Acidic Range pH 4-7 for 24-cm IPG Strips 03

Voltage mode	Voltage(V)	Duration (h:min)	Volt-hours (kVh)
1. Step	3500	_	75
2. Gradient	1000	0:10	
3. Step	8000	1:00	<b>—</b>
4. Step and hold	100	>24 h	<u> </u>

12 4. Overlay each strip with  $\sim 2$  mL of IPG strip cover fluid to prevent evaporation and slide on the plastic cover. Cover with aluminum foil and incubate overnight 13 (or at least 10 h) at room temperature. Low voltage applied during rehydration 14 can improve entry of high molecular weight protein (13). 15

5. After adequate rehydration, use clean forceps to remove the IPG strips from 16 the rehydration tray. Blot off excess fluid and carefully position the IPG strips 17 (gel side up) within the ceramic manifold of the IPGphor isoelectric focusing 18 unit (GE Healthcare). Ensure that the positive (anodic) end of each strip is 19 oriented toward the anode of unit.

20 6. Apply one filter paper electrode pad, which has been moistened with de-ionized 21 water (remove excess fluid with blotting paper), to each end of the IPG strip 22 in such a way as to overlap the gel by approximately 3 to 5 mm. Place the 23 respective electrodes over the filter paper pads and clip firmly in place and overlay each strip with cover fluid to prevent dehydration (108 mL for whole 24 manifold). 25

7. Close the IPGphor IEF unit safety lid and the instrument running conditions can 26 be programmed. We suggest conditions appropriate to proteins soluble within 27 the acidic range pH 4-7, for 24-cm IPG strips (Table 3). Current should be limited to 50 µA per IPG strip. Other run conditions for the various strip sizes 29 and pH ranges are available [Ettan IPGphor manifold user manual (80-6499-52 30 edition AO); GE Healthcare]. 31

8. Once the strips have been focused, they can be equilibrated straight away for the second dimension or stored for several months at -80°C between plastic sheets to prevent damage to the brittle frozen strips.

#### 33 34 35

36

32

28

# 5. SECOND-DIMENSION SDS-PAGE (2-DE)

In order to improve protein migration from focused IPG strip to the 37 second-dimension separation gel, it is important to equilibrate the strips in a 38 buffer containing sodium dodecyl sulfate (SDS), urea, and glycerol. In the 39 first equilibration step, DTT is added to completely reduce any remaining 40 41 disulfide bonds, whereas iodoacetamide is added in the second step to

AQ5

alkylate the resultant sulfydryl groups thereby preventing reoxidation, 01 which may complicate downstream mass spectrometry identification. In 02 addition, the iodoacetamide "mops up" any free DTT, which may otherwise 03 cause point-streaking artifacts, apparent in silver-stained gels. The Protean 04 Plus Dodeca multiple gel unit (Biorad) is used in the worked example, 05 as it can accommodate up to 12 large-format slab gels, has an in-built 06 buffer recirculation and cooling system and plate electrodes for consistent 07 resolution. A recipe for a 12% homogenous polyacrylamide Tris-glycine 08 gel is also given using stabilized, high-purity Protogel reagents (National 09 Diagnostics), though gradient gels and other buffer systems may give 10 better resolution for select protein molecular weight ranges (14,15). It 11 should be noted that the nature of the Cy dyes used in the DIGE technique 12 necessitate the use of specialized low-fluorescence glass plates. The glass 13 plates require thorough cleaning with dilute alcohol and de-ionized water 14 using lint-free tissues to remove any dried salts or gel fragments prior to 15 casting. 16

# Beforehand: Prepare Equilibration Buffer and Gels

- 1. Prepare the stock SDS Equilibration buffer [50 mM Tris pH 8.8, 6 M urea, 19 30% (v/v) glycerol, 2% SDS (w/v)] (10 mL per strip will be required, excess 20 can be aliquoted and stored at  $-20^{\circ}$ C for future use). 21
- 2. Prepare the working-strength Gel Running buffer [25 mM Tris base, 192 mM 22 glycine, 0.1% SDS (w/v)] (up to 25 L is required to fill the Dodeca gel tank). 23
- 3. Prepare 600 mL of gel casting solution (sufficient for six 1.0-mm, 12% gels; 24 100 mL per gel) [240 mL 30% (w/v) acrylamide/methylene bisacrylamide 25 solution (37.5:1 ratio), 156 mL 4X Laemmli Resolving Gel buffer (0.375 Tris-26 HCl pH 8.8, 0.1% SDS final concentration, 197.4 mL de-ionized water, 240 µL 27
  - TEMED, 2.4 mL of 10% (w/v) ammonium persulfate (APS)]. Pass the solution through an 0.2-µm filter and degas under vacuum, prior to the addition of APS.
- 4. Apply waterproof adhesive tape to the sides of assembled glass plates and spacers, place into the gel caster with plastic sheet spacers, and gradually pour 30 in the prepared mixture. Carefully layer  $\sim 2$  mL of water-saturated butanol on top of each gel to remove bubbles and create a level surface. Flush the butanol off the gels with double de-ionized water after approximately 1 h and cover the casting unit with tin foil. Ideally, gels should be cast the day before use to ensure complete polymerization.
- 35 5. Prepare a 1.0% agarose solution in Gel Running buffer with 50 mg bromophenol 36 blue incorporated per 100 mL. Dissolve the agarose by a short incubation in a 37 microwave on low-medium power.

#### **IPG Strip Equilibration** 39

40 1. Prepare Equilibration buffer A by dissolving 100 mg of DTT per 10 mL of stock SDS Equilibration buffer (5 mL needed per IPG strip). Dispense a 5-mL 41

198

17

18

28

29

31

32

33

34

38

AQ8

AQ6

AQ7

aliquot of buffer A into equilibration tubes and place the IPG strips carefully into each. (Disposable plastic 10-mL pipettes with the conical tip broken off are sufficiently long; reseal with parafilm between incubations.) Incubate the strips at room temperature with gentle rocking for 15 min, then decant the buffer.

Prepare buffer B by dissolving 250 mg of iodoacetamide per 10 mL of stock 2. SDS Equilibration buffer (5 mL needed per IPG strip). Dispense a 5-mL aliquot of buffer B into each equilibration tube and reseal. Equilibrate the strips for a further 15 min at room temperature with gentle rocking, decant the buffer, and proceed to electrophoresis section.

#### SDS-PAGE 11

01

02

03

04

05

06

07

08

09

10

28

31

12 1. Rinse the equilibrated IPG strips in Gel Running buffer and using forceps place 13 each strip across the top of a gel, such that the plastic backing of the strip 14 makes contact with the back glass plate and the anodic end of the strip is at the 15 top left of the gel. A thin spatula can then be used to maneuver the strip down into the well, with care so no bubbles are introduced between strip and gel. 16 A good tip is to push one end of the IPG strip down, between the glass plates, 17 so it makes contact with the top of the gel and gradually push the opposite end 18 down so the strip sits level on the surface. 19

2. Layer approximately 2 mL of premelted 1% agarose sealing solution carefully 20 across the strip, again try to eliminate any air bubbles trapped between the strip 21 and gel. Allow to cool and solidify for 5 min and repeat the procedure for the 22 outstanding IPG strips.

23 3. Insert the prepared gel cassettes into position in the electrophoresis unit (this 24 can be made easier by prewetting each cassette by dipping it briefly into the 25 Gel Running buffer). Ensure the buffer chamber is filled to the manufacturer's 26 recommended level and place the safety lid on paying attention to the orientation of the electrodes. 27

4. Start the electrophoresis with 2 W per gel for 45 min followed by 17 W per gel for 4 h, both at 20°C. Alternately, for convenience, the gels can be run 29 overnight at 0.75 W per gel. (Such an overnight run can take anything from 18 30 to 21 h.) The run should be terminated when the bromophenol blue dye front reaches the bottom of the gel. 32

5. In preparation for scanning the gels, the scanner instrument should be switched 33 on and left to warm up for 30 min and the glass plate should be thoroughly 34 cleaned with lint-free tissues. As DIGE gels are scanned while they are in the 35 glass cassettes, these too should be cleaned carefully to remove any residual 36 running buffer, gel smears, and so forth, from the surface of the plates. If 37 not scanned immediately, gels can be individually wrapped in cling film and 38 stored at 4°C but should be imaged as soon as possible to avoid signal loss and dissipation of focused spots. Gels stored at 4°C should also be allowed to come 39 up to room temperature before scanning to avoid any condensation forming on 40 41 the surface of the glass.

AO9

### **6. IMAGE ACQUISITION**

02 The capture of gel image data is a critical stage in the whole analysis 03 workflow that can often present a source of easily prevented experimental 04 noise. It is possible to make careless choices at this stage that can result in 05 a 200-fold drop in sensitivity. A variety of DIGE-compatible gel scanning 06 instruments based on charge-coupled device (CCD) or photomultiplier 07 tube (PMT) detection technologies are available (GE Healthcare, Typhoon; 08 Syngene, ChemiGenius; Fuji, FLA 1500; Biorad, FX Molecular Imager). 09 Depending on the make of scanner, there are several parameters to optimize; 10 the spatial resolution, the dynamic range, the scan content, and background 11 offsets. These features are therefore briefly discussed and recommendations 12 made in each case to improve the process of image acquisition. 13

14 15

16

# 6.1. Spatial Resolution

Image (or spatial) resolution relates to the number of pixels (picture 17 elements) displayed per unit length of a digital image and is often measured 18 in dots per inch (dpi) or in micrometers (the size of the area each pixel 19 represents). Images with a higher spatial resolution are composed of a greater 20 number of pixels and have more image detail that those of lower spatial 21 resolution. It is important to be aware that variations in spatial resolution will 22 not only affect the final appearance of the image but will also impinge on 23 the quality of spot detection and the accuracy of any subsequent quantitative 24 measurements. 25

At low resolutions, there are fewer pixels available to represent each spot, and as a result, spot detection and quantitative accuracy will be compromised. Image (spatial) resolution is illustrated in more detail in **Fig. 2**. Higher resolution means that more pixels, and hence more data, are available for the analysis: the spot highlighted in red in **Fig. 3** is represented by 63 pixels at a relatively low 100 dpi resolution (**Fig. 2A**), compared with 485 pixels at a higher 300 dpi resolution (**Fig. 2B**).

There is, however, a maximum resolution, which once exceeded produces 33 minimal additional information. Once resolution is sufficient to adequately 34 represent the smallest features, any further increases in spatial resolution 35 simply increase the ability to represent the system "noise." In addition, 36 every doubling in spatial resolution quadruples the amount of data that has 37 to be processed, which can cause problems in processing speed and file and 38 memory management. For example, a typical  $20 \times 20$  cm DIGE single dye 39 image captured at 100 dpi versus 300 dpi would result in diverse file sizes 40 41 of 1.2 Mb and 10.6 Mb, respectively (both at 16-bit depth).



**Fig. 2.** Portions of two-dimensional gel image scans showing typical image quality, spot outline, and three-dimensional spot intensity (top to bottom) at 100 dpi (8-bit) and 300 dpi (16-bit) resolutions

To summarize, in most situations, 300 dpi or 100 µm will provide an image that is large enough for accurate analysis and small enough for efficient processing. However, if your gels are small (e.g., minigels), then you may need to increase the resolution to achieve this. As a rule of thumb, the active area of the gel (i.e., the area of spot material) should fall in the range 1000 to 1800 pixels in both horizontal and vertical directions. This range provides a good trade-off in information content and analysis performance. 

# <sup>30</sup><sub>31</sub> 6.2. Dynamic Range (Bit Depth)

Also referred to as color depth, bit depth or pixel depth is the number of bits used to represent the color (grayscale, intensity levels) of each pixel in an image. Greater bit depth allows a greater range of colors or shades of gray to be represented by a pixel. If possible, scan at 16-bit rather than 8-bit. The bit depth of a 16-bit image (65,536 levels of grayscale) compared with an 8-bit image (256 levels of grayscale) results in enhanced sensitivity and accuracy of quantification for less-abundant proteins. The possible grayscale levels available along with the resultant dynamic range (orders of magnitude) for the types of images commonly used in two-dimensional gel image analysis are indicated in **Table 4**. In reality, the images displayed on the computer

AQ10

\_\_\_\_\_]



202

Fig. 3. Schematic representation of the processes involved in DIGE image analysis. (see Color Plate 4, following p. x)

28 29

26

27

screen will only be represented in 256 shades of gray, and so an 8-bit 30 image will look identical to a 16-bit image by eye. However, image analysis 31 software can distinguish between the different levels of gray. As a rule, 32 the more levels of gray represented in an image, the better the ability to 33 differentiate low-abundance spots from background, and the greater the 34 quantitative accuracy. This is further illustrated in Fig. 2, comparing spot 35 detection in an identical area on the same two-dimensional gel, captured at 36 8-bit and 16-bit, respectively. 37

The dynamic range can be adjusted in CCD camera systems by altering 38 the exposure time and in laser-based systems by fine tuning the voltage of 39 the PMT detector. The dynamic range should be optimized to maximize 40 41 the use of available grayscale values. Aim for the maximum gray levels

#### 01 Table 4

02

03

25

26

The Resultant Grayscale Levels and Dynamic Range (Orders of Magnitude) Are Shown for a Range of Image Bit Depths Commonly Used to Analyze Two-dimensional Gels

Bit depth	Intensity (grayscale) levels	Orders of magnitude	Percent of 16-bit scan
8	$256(2^8)$	2.4	0.39
10	$1024(2^{10})$	3.01	1.56
12	$4096(2^{12})$	3.6	6.25
16	$65,536(2^{16})$	4.8	100

in the image to be 5% to 10% less than those available. Scanner response 14 curves can be nonlinear, and inconsistent settings can cause issues. For 15 DIGE experiments without a Cy2 internal standard, chose settings that 16 optimize the dynamic range for each stain and keep these consistent. When 17 optimizing the dynamic range, it is important to avoid saturation effects. 18 Saturation occurs when gray levels exceed the maximum available. When a 19 spot becomes saturated, any differences in high pixel intensities cannot be 20 resolved, and the spot appears truncated when viewed in three dimensions. 21 No reliable quantitative data can be generated from a saturated spot, and 22 saturated spots may also have an overall effect on normalization if included 23 in later analysis. 24

# 6.3. Scan Content

Wherever possible, it is best to try to keep the area scanned as valid gel 27 area. It is common to see scans where there are lots of scanner bed, labels, 28 and so forth, in the captured image. Some scanners automatically adjust the 29 scan settings based on what they "see" so a significant proportion of the 30 dynamic range is lost by representing scanner bed or labels. It may be best 31 to switch off auto gain control features or, at least, outline the areas you 32 are interested in so the scanner optimizes only the region of interest. Extra 33 "non gel" areas provide no useful information and should be cropped prior 34 to image analysis. These scanning artifacts can skew the image statistics, 35 "steal" dynamic range, increase storage requirements, and cause extra work 36 in manual stages of analysis. Another good tip for consistency (and to save 37 time later) is to always scan gel images using the same orientation and with 38 the same settings. 39

Postscan processing of two-dimensional gel images using Adobe
 Photoshop or other general image processing software should be avoided, as

these do not maintain the integrity of your original data, and any calibration 01 information contained in the image file will be lost. The manipulations 02 may make the images "look better" to the human eye but are simply trans-03 forming the original data. If the images look bad in the first place, then you 04 should try to optimize the scanning not manipulate the images digitally. If 05 possible, use GEL or IMG/INF files formats rather than generating TIFF 06 files. The former often contain additional grayscale calibration information, 07 which will not be included in the TIFF version. In any case, do not use 08 JPEG file storage format as it is a standard for "lossy" image compression, 09 which is optimized to allow the loss of information that is least noticeable 10 to the human eye. This does not mean it does not affect measures made by 11 computers. Lossy compression throws information away and manipulates 12 the image data. Converting a JPEG image back to a TIFF is not a solution; 13 once the image has been compressed in this way, the data has been lost and 14 cannot be retrieved. 15

#### 16 17

18

### 7. IMAGE ANALYSIS: SOFTWARE PRINCIPLES AND WORKFLOWS

19 Image analysis of conventional silver or Coomassie stained two-20 dimensional gels of individual samples can be highly subjective and very 21 time consuming, due to inherent unpredictable distortions between gels. 22 These inconsistencies prevent the perfect alignment and matching of spots 23 between gels. On the other hand, DIGE-derived images from the same gel are 24 precisely superimposable, and gel to gel spot matching is uniquely assisted 25 by the internal standard (Cy2 labeled). So by virtue of the prelabeling and 26 comigration of differentially labeled samples, variation in spot "coordi-27 nates" and intensity are accounted for, and gel images analysis is much 28 more efficient (16). It is important to understand the principles that tradi-29 tional software applications apply, highlight their limitations, and provide a 30 recommended analysis workflow (depicted in Fig. 3 and see Color Plate 4, 31 following p. x).

32 33

34

# 7.1. Image Warping and Spot Matching

The biggest problem in the image analysis of a gel-based experiment is data alignment. This is easy to see by comparing the state of the art statistical analysis for array-based experiments and the sorts of analysis performed on gel-based systems. The key difference between the two workflows is that the exact locations of data points are known in the array scenario. In traditional two-dimensional gel analysis, the alignment issue is tackled by a between gel spot matching stage. Most traditional analysis strategies follow

these key steps; detect spots on each gel individually, attempt to match the spots across the experiment (possibly with the assistance of whole image gel warping), measure spots, apply some form of normalization, apply statistical analysis (17). The recommended workflow (**Fig. 3**) is distinguished by initially warping gels, then matching and delineating spots, and imposing the same spot outlines across all gels prior to quantification.

The main problem with the traditional workflow is that it is not able 07 to provide data of sufficient quality required to perform advanced statis-08 tical analysis. The core issue is focused on missing values; that is, a data 09 point (usually a spot) that is not available across all samples. A recent 10 study measured 42% missing values (i.e., not experimentally induced data 11 omission) for a 16-gel experiment (18). It has also been shown that the 12 number of missing values increases with the number of replicates (19). This 13 produces the predicament of reducing the extent and quality of data, as 14 the investigator endeavors to improve statistical power by increasing the 15 number of replicates. In the traditional analysis workflow, missing values 16 arise from two main sources: (1) the same measurements not being taken 17 from each gel (usually due to spot detection) and (2) the measurements not 18 being correctly matched between gels. 19

The same measurement not being taken from each gel has two main 20 effects. The first is down to the fact that in traditional analysis scenarios, 21 each gel has spots detected in isolation. This can lead to inconsistent results 22 because essentially the pattern is determined from a single instance and 23 as such is more prone to technical variance. The second issue is usually 24 attributed to experimental conditions where a spot has zero expression in 25 one or more of the groups. In this case, a spot will not be detected on an 26 individual gel basis, and we are left with a hole in the data. Strangely, the 27 proteomics community tends to differ with standard scientific practice with 28 zero expression spots preferring to have no measurement or "unmatched" 29 rather than measuring the value "zero." This is analogous to measuring 30 air temperature and saying "there was no temperature" when it hits zero 31 instead of measuring and recording zero. This particular stance also forces 32 a multiple instead of a unified statistical framework approach to analysis, 33 which is laborious, prone to bias, and still may be suboptimal. 34

35 36

37

# 7.2. Spot Delineation/Outline

Geometric correction alone does not solve all of the issues as we would still be prone to threshold of detection issues on a per gel basis and also not matching spots that were not expressed in certain groups. The obvious next step is to stabilize and standardize the spot detection across all of the

images within an experiment. The geometric correction combined with an 01 "ensemble," experiment-wide, spot pattern would go a large way to not only 02 removing the bulk of missing values but also removing a large amount of 03 manual intervention. We would also gain most in the low-expression spots 04 that are harder to detect consistently on a per gel basis. If we apply geometric 05 correction and derive a suitable outline for spots that are not undergoing 06 experimentally induced variation, then the software can handle more than 07 half (usually more) of the spots in an experiment fully automatically. This 08 is essentially reverse logic where it is more efficient to bias the analysis to 09 discount what is not changing rather than to optimize for what may be. This 10 also removes the situation where you have to spend a lot of time editing 11 a series of spots to find "they don't change." Considering the efficiency 12 of overall analysis, applying the same spot outlines across geometrically 13 corrected images is advantageous, and the benefits increase as the number 14 of spots subject to experimentally induced expression changes decreases. 15 A restriction imposed by the same spot outlines is that the area considered 16 to contain a spot is consistent across images. This means that there are only 17 going to be issues if the expression change is so large that it cannot be 18 represented by the same area across the gels. For spots in isolation, this is 19 not an issue as a larger area can be used (any extra pixels included in the 20 larger boundary will be zero in the smaller spots). Tight clusters of spots 21 that vary slightly in location and potentially patterns of spots that overlap 22 when considered across all groupings may however prove problematic and 23 require additional editing. Interestingly, posttranslational modification shifts 24 of proteins are better handled by the same outlines workflow than the 25 traditional approach, as one can apply a robust statistical framework to 26 discovering them. Therefore, contrary to current practice and "gut feel," 27 it appears to be more favorable to apply the same spot outline pattern to 28 geometrically corrected gels and robustly analyze the bulk of the spots 29 within the experiment in a "first pass" with minimal manual intervention 30 and hence bias. 31

Once the same outlines analysis has been completed, one will have a list 32 of "interesting" areas. These will either be completely satisfactory with the 33 automatic outlines or it may be deemed that editing should be considered. It 34 is advisable that the initial analysis be completed fully without intervention 35 and this analysis saved. From this, a list of areas for further examination 36 should be made and these explored in a mode that adds to the information 37 and not replaces it. At this point, we may consider editing outlines. The 38 editing process is less biased when one uses the same outline across all 39 gels within the experiment. This is because the volume of a spot is affected 40 41 by the number of pixels chosen to include in its boundary; if imposed

inconsistently between groups, it is easy to introduce unintentional bias. 01 Because there is a much reduced requirement on manual intervention, one 02 can spend a lot more time on the areas that matter. Feedback from multiple 03 labs has shown that differential editing is rarely necessary at all and, if it 04 is, tends not to be a major factor in the results of the experiment. Areas 05 where this is deemed necessary should always be treated with caution and 06 may be a target area for future experiments where the zoom gels are used or 07 alterations to the sample preparation improve the data quality in these areas. 08

- $\frac{10}{10}$  In summary, the suggested workflow is
- 1. Geometrically correct your gels.
- $_{12}$  2. Create a spot pattern representative of all of the spots within your experiment.
- $_{13}$  3. Analyze the spots completely.
- 4. Complete statistical analysis.
- 5. Create a copy of the experiment and edit/apply differential outlines on areas
   where it is deemed strictly necessary.
   Complete striction englying
  - 6. Complete statistical analysis.

17

18

30

31

# 8. PREPARATIVE GELS FOR SPOT PICKING

19 Because DIGE offers superlative sensitivity to quantify minute differ-20 ences in protein expression levels, relative to conventional staining 21 techniques, sample load is reduced accordingly (from as low as 75 µg to 22 200 µg per gel). Once spots of interest have been identified, it is then 23 necessary to run a "preparative" gel with a higher sample loading (0.5 mg to 24 2.0 mg) ensuring sufficient protein in these spots to obtain reliable identifi-25 cations by mass spectrometry (20). A spot "pick list" can be generated, such 26 that isoelectric point and molecular weight coordinate data derived from 27 the DIGE "analytical" gels can be transposed onto a Coomassie or silver 28 stained gel. 29

9. CONCLUSION

Whereas the concept of DIGE is relatively novel, it has unique attributes 32 that make it particularly suitable in the drug and biomarker discovery 33 process. Because the technique is not dependent on antibody-protein 34 or oligonucleotide-RNA/DNA affinity, it does not preclude the target 35 identity, therefore represents changes in the sample without preemptive bias. 36 Although extended multiplex capability and an increased dynamic range are 37 desirable, it remains the most sensitive validated gel-based proteomic tool 38 with direct relevance to innovation in clinical and pharmaceutical research. 39 Improvements in dedicated analytical software have greatly increased the 40 41 throughput and confidence in data derived from DIGE images. DIGE holds

AQ11

much promise in the challenge to uncover new molecular targets, screen
 putative drug efficacy, and monitor therapeutic response for a wide range
 of debilitating diseases.

# 05 **REFERENCES**

- <sup>06</sup> 1. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins.
   <sup>07</sup> J Biol Chem 1975;250(10):4007–4021.
- Marouga R, David S, Hawkins E. The development of the DIGE system:
   2D fluorescence difference gel analysis technology. Anal Bioanal Chem
   2005;382(3):669–678.
- 3. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997;18(11):2071–2077.
- 4. Tonge R, Shaw J, Middleton B, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001;1(3):377–396.
- <sup>16</sup> 5. Alban A, David SO, Bjorkesten L, et al. A novel experimental design
   <sup>17</sup> for comparative two-dimensional gel analysis: two-dimensional difference
   <sup>18</sup> gel electrophoresis incorporating a pooled internal standard. Proteomics
   <sup>19</sup> 2003;3(1):36–44.
- 6. Wu WW, Wang G, Baek SJ, Shen RF. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res 2006;5(3):651–658.
- 7. Lilley KS, Friedman DB. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev Proteomics 2004;1(4): 401–409.
- <sup>25</sup> 8. Karp NA, Lilley KS. Maximising sensitivity for detecting changes in protein expression: experimental design using minimal CyDyes. Proteomics 27 2005;5(12):3105–3115.
- 9. GE Healthcare. Ettan DIGE System User Manual. AB(18–1173–17). GE
   Healthcare, 2006:1–112.
- 10. Gorg A, Drewes O, Weiss W. Separation of proteins using two-dimensional
   gel electrophoresis. In: Simpson RJ, ed. Purifying Proteins for Proteomics—A
   Laboratory Manual. New York: CSHL Press, 2003:391–430.
- 11. Gibson DS, Blelock S, Brockbank S, et al. Proteomic analysis of recurrent joint inflammation in juvenile idiopathic arthritis. J Proteome Res 2006;5(8): 1988–1995.
   15. 1988–1995.
- <sup>35</sup> 12. Gorg A, Obermaier C, Boguth G, et al. The current state of twodimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000;21(6):1037–1053.
- <sup>38</sup> 13. Gorg A, Obermaier C, Boguth G, Weiss W. Recent developments in twodimensional gel electrophoresis with immobilized pH gradients: wide pH
   <sup>40</sup> gradients up to pH 12, longer separation distances and simplified procedures.
- 41 Electrophoresis 1999;20(4–5):712–717.

# 208

14. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227(5259):680-685. 15. Anderson NL, Anderson NG. Analytical techniques for cell fractions. XXII. Two-dimensional analysis of serum and tissue proteins: multiple gradient-slab gel electrophoresis. Anal Biochem 1978;85(2):341-354. 16. Corzett TH, Fodor IK, Choi MW, et al. Statistical analysis of the experimental variation in the proteomic characterization of human plasma by two-dimensional difference gel electrophoresis. J Proteome Res 2006;5(10):2611-2619. 17. Fodor IK, Nelson DO, Alegria-Hartman M, et al. Statistical challenges in the analysis of two-dimensional difference gel electrophoresis experiments using DeCyder. Bioinformatics 2005;21(19):3733-3740. 18. Grove H, Hollung K, Uhlen AK, Martens H, Faergestad EM. Challenges related to analysis of protein spot volumes from two-dimensional gel electrophoresis as revealed by replicate gels. J Proteome Res 2006;5(12):3399–3410. 19. Houtman R, Krijgsveld J, Kool M, et al. Lung proteome alterations in a mouse model for nonallergic asthma. Proteomics 2003;3(10):2008–2018. 20. Mahnke RC, Corzett TH, McCutchen-Maloney SL, Chromy BA. An integrated proteomic workflow for two-dimensional differential gel electrophoresis and robotic spot picking. J Proteome Res 2006;5(9):2093-2097. 

AQ1       192       02       Provide location of Roche.         AQ2       192       07       Provide name and location of manufacturer.         AQ3       192       31       Provide location of manufacturer.         AQ4       194       31       We have italicized the underfined words throughout the text and table. Please check.         AQ5       197       Table 3       In Table 2, define acronym DLB.         AQ6       198       05       Provide location of manufacturer.         AQ7       198       10       Provide location of manufacturer.         AQ8       198       26       Define acronym TEMED.         AQ9       200       08       Provide locations for Syngene and Fuji.         AQ10       200       18       Explain parts A and B in the legend add part label to Fig. 2 legend.         AQ11       208       28       In Ref. 9, provide location of manufacturer a publisher.	Query No.	Page No.	Line No.	Query
AQ2       192       07       Provide name and location of manufacturer.         AQ3       192       31       Provide location of manufacturer.         AQ4       194       31       We have italicized the underfined words throughout the text and table. Please check.         AQ5       197       Table 3       In Table 2, define acronym DLB.         AQ6       198       05       Provide location of manufacturer.         AQ7       198       10       Provide location of manufacturer.         AQ8       198       26       Define acronym TEMED.         AQ9       200       08       Provide locations for Syngene and Fuji.         AQ10       200       18       Explain parts A and B in the legend add part label to Fig. 2 legend.         AQ11       208       28       In Ref. 9, provide location of manufacturer a publisher.	AQ1	192	02	Provide location of Roche.
AQ3 192 31 Provide location of manufacturer. AQ4 194 31 We have italicized the underlined words throughou the text and table. Please check. AQ5 197 Table 3 In Table 2, define acronym DLB. AQ6 198 05 Provide location of manufacturer. AQ7 198 10 Provide location of manufacturer. AQ8 198 26 Define acronym TEMED. AQ9 200 08 Provide locations for Syngene and Fuji. AQ10 200 18 Explain parts A and B in the legend add part label to Fig. 2 legend. AQ11 208 28 In Ref. 9, provide location of manufacturer a publisher.	AQ2	192	07	Provide name and location of manufacturer.
AQ4       194       31       We have italicized the underlined words throughout the text and table. Please check.         AQ5       197       Table 3       In Table 2, define acronym DLB.         AQ6       198       05       Provide location of manufacturer.         AQ7       198       10       Provide location of manufacturer.         AQ8       198       26       Define acronym TEMED.         AQ9       200       08       Provide locations for Syngene and Fuji.         AQ10       200       18       Explain parts A and B in the legend add part label to Fig. 2 legend.         AQ11       208       28       In Ref. 9, provide location of manufacturer a publisher.	AQ3	192	31	Provide location of manufacturer.
AQ5 197 Table 3 In Table 2, define acronym DLB. AQ6 198 05 Provide location of manufacturer. AQ7 198 10 Provide location of manufacturer. AQ8 198 26 Define acronym TEMED. AQ9 200 08 Provide locations for Syngene and Fuji. AQ10 200 18 Explain parts A and B in the legend add part label to Fig. 2 legend. AQ11 208 28 In Ref. 9, provide location of manufacturer a publisher.	AQ4	194	31	We have italicized the underlined words throughout the text and table. Please check.
AQ6 198 05 Provide location of manufacturer. AQ7 198 10 Provide location of manufacturer. AQ8 198 26 Define acronym TEMED. AQ9 200 08 Provide locations for Syngene and Fuji. AQ10 200 18 Explain parts A and B in the legend add part label to Fig. 2 legend. AQ11 208 28 In Ref. 9, provide location of manufacturer a publisher.	AQ5	197	Table 3	In Table 2, define acronym DLB.
AQ7 198 10 Provide location of manufacturer. AQ8 198 26 Define acronym TEMED. AQ9 200 08 Provide locations for Syngene and Fuji. AQ10 200 18 Explain parts A and B in the legend add part label to Fig. 2 legend. AQ11 208 28 In Ref. 9, provide location of manufacturer a publisher.	AQ6	198	05	Provide location of manufacturer.
AQ8 198 26 Define acronym TEMED. AQ9 200 08 Provide locations for Syngene and Fuji. AQ10 200 18 Explain parts A and B in the legend add part label to Fig. 2 legend. AQ11 208 28 In Ref. 9, provide location of manufacturer a publisher.	AQ7	198	10	Provide location of manufacturer.
AQ9       200       08       Provide locations for Syngene and Fuji.         AQ10       200       18       Explain parts A and B in the legend add part label to Fig. 2 legend.         AQ11       208       28       In Ref. 9, provide location of manufacturer a publisher.	AQ8	198	26	Define acronym TEMED.
AQ10 200 18 Explain parts A and B in the legend add part label to Fig. 2 legend. AQ11 208 28 In Ref. 9, provide location of manufacturer a publisher.	AQ9	200	08	Provide locations for Syngene and Fuji.
AQ11 208 28 In Ref. 9, provide location of manufacturer a publisher.	AQ10	200	18	Explain parts A and B in the legend add part label to Fig. 2 legend.
publisher.	AQ11	208	28	In Ref. 9, provide location of manufacturer a
				publisher.
			2	
S				
S				
S				
5				
5				
5				
5				

01 Chapter-9